Foghorn Therapeutics Inc. Cash Flow Statement

Cash Flow Statement Dec2019 Dec2020 Dec2021 Dec2022 Dec2023 Dec2024
Operating Activities
Net Income -51.62M-69.51M-102.58M-108.88M-98.43M-86.62M
Share-based Compensation 1.69M2.96M8.38M14.34M16.19M11.89M
Gains from Investment Securities -0.00M0.07M3.55M0.86M
Asset Writedowns and Impairment 2.40M
Cash from Operations -46.34M-31.29M-50.25M193.61M-118.11M-100.41M
Depreciation, Depletion & Amortization
Amortizatization of Intangibles 0.00M-0.18M1.29M2.65M4.61M
Amortization of Deferred Charges 0.10M0.24M0.32M
Depreciation & Amortization (CF) 0.69M1.33M3.23M3.32M3.50M3.12M
Change in Working Capital
Change in Account Payables 1.21M0.47M0.14M1.61M0.85M-2.48M
Change in Accured Expenses 2.14M3.19M2.65M1.44M-1.80M-0.56M
Investing Activities
Capital Expenditures 0.97M16.18M3.31M1.21M1.22M0.91M
Sales of Property, Plant and Equipment 0.00M0.25M
Change in Acquisitions & Divestments 139.47M166.23M219.57M232.47M
Cash from Investing Activities -0.96M-108.91M36.17M-244.32M144.45M-29.90M
Financing Activities
Other financing activities 0.58M
Debt Issuance and Repayment
Long-Term Debt Issuances 7.98M19.80M
Long-Term Debt Repayments 15.53M21.20M
Change in Capital Stock
Shares Issued 0.69M122.12M42.20M1.76M1.78M103.40M
Preferred Shares Issued 15.29M89.86M
Misc.
Cash from Financing Activities 23.97M217.47M22.42M1.76M1.78M105.43M
Change in Cash -23.33M77.27M8.34M-48.95M28.12M-24.88M
Free Cash Flow -47.30M-47.47M-53.56M192.40M-119.33M-101.31M
Net Cash Flow -23.33M77.27M8.34M-48.95M28.12M-24.88M